Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$77.26 USD
-1.50 (-1.90%)
Updated Oct 10, 2024 04:00 PM ET
After-Market: $77.26 0.00 (0.00%) 4:48 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Price, Consensus and EPS Surprise
RDY 77.26 -1.50(-1.90%)
Will RDY be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for RDY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RDY
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock
Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug
RDY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat
Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
Other News for RDY
Alvotech application for Prolia/Xgeva biosimilar accepted by EMA
Dr. Reddy’s Announces Subsidiary’s Liquidation
U.S. government to release preliminary list for pilot Medicare program offering generics under $2 - report
Aurigene Oncology announces results of Phase 1 study of DRL-1801
Dr. Reddy’s Subsidiary Triumphs in CAR-T Cell Therapy Trial